勃林格与Hydra达成第2项合作专注肾脏病领域

2015年4月13日讯/生物谷BIOON/--德国制药巨头勃林格殷格翰（BI）近日与瞬时受体电位（TRP）通道调制领域的的领导者HydraBioSciences公司签署了一项全球研究合作及授权协议，鉴别并开发小分子瞬时受体电位（TRP）抑制剂用于肾脏疾病的治疗。此次合作也标志着勃林格与Hydra之间的第二次合作。去年4月，双方达成了首次研发合作，开发TRPC4/5抑制剂，用于治疗中枢神经系统（CNS）疾病和失调。
根据协议条款，双方将携手合作，鉴定并推进候选抑制剂。勃林格将负责来自合作的抑制剂的全球开发和商业化。Hydra公司将获得预付款、额外研究经费，并有资格获得里程碑款项和未来产品销售的特许权使用费。
HydraBiosciences公司总部位于美国马萨诸塞州剑桥市，是一家私人持有的生物制药公司，拥有专有的离子通道技术和高通量筛选平台，能够高效识别和发现新的候选化合物，开发用于治疗疼痛、炎症、焦虑等疾病的药物。
HydraBiosciences公司的专有平台能够鉴别和发现有望解决远未满足医疗需求的首创新药，其管线资产包括靶向TRPA1、TRPC4/C5、TRPV3、TRPV4、CatSper等离子通道的抑制剂。目前，该公司已与多家制药企业达成合作，将其最先进的高通量筛选设备和深厚的离子通道专业知识用于推动多个领域候选药物的开发。
英文原文：HydraBiosciencesandBoehringerIngelheimEnterResearchCollaborationFocusedonRenalDiseasesandDisorders
CAMBRIDGE,MassachusettsandINGELHEIM,Germany–April13,2015-HydraBiosciences,Inc.,aleaderinthefieldoftransientreceptorpotential(TRP)channelmodulation,andBoehringerIngelheimtodayannouncedthattheyhaveenteredintoaworldwideresearchcollaborationandlicenseagreementtoidentifysmall-moleculeTRPinhibitors,withaprimaryfocusonthetreatmentofrenaldiseasesanddisorders.
“ThispartnershipbetweenBoehringerIngelheimandHydraBiosciencesprovidesanexcellentopportunitytomaximizethepotentialofnoveltargetsthatmayoffermeaningfulimprovementsinthetreatmentofchronickidneydiseasesandotherrelateddiseasesanddisorders.BoehringerIngelheim’slongtrackrecordofresearch,developmentandcommercializationsuccessmakesthemtheperfectpartnerforthisprogram,”saidRussellHerndon,PresidentandCEOofHydraBiosciences.
ThismarksthesecondcollaborationbetweenBoehringerIngelheimandHydraBiosciencesasthetwocompanieslastyearbegancollaboratingtoresearchanddevelopsmall-moleculeTRPC4/5inhibitorsforthetreatmentofcentralnervoussystem(CNS)diseasesanddisorders.
“ThisnewcollaborationagreementwithHydraBiosciencesreflectstheimportanceandvalueBoehringerIngelheimplacesindevelopingstrongresearchpartnershipstodiscovernewtreatmentsforrenaldiseasesandrelateddisorders,”saidDr.MichelPairet,SeniorCorporateVicePresidentofResearchandNon-clinicalDevelopmentatBoehringerIngelheim.Headded,“WeareveryexcitedtobeabletocontinuetoworktogetherwithHydraBiosciences.RenaldiseasesanddisordersareofincreasingimportancetoBoehringerIngelheimaspartofourCardioMetabolicDiseasesResearcharea,andourdedicatedrenaldiseaseresearchunitbasedinRidgefield,CT,USA,isconstantlyexpandingitsnetworkofpartnershipsinthisfield.”
Underthetermsofthecollaborationagreement,thecompanieswillworktogethertoidentifyandadvancecandidateinhibitors.BoehringerIngelheimisresponsiblefortheglobaldevelopmentandcommercializationoftheinhibitorsthatcomefromthecollaboration.Hydrawillreceiveanundisclosedupfrontpayment,additionalresearchfunding,andtheCompanyiseligibletoreceivemilestonepaymentsandtieredroyaltypaymentsonfutureproductsales.
AboutHydraBiosciencesHydraBiosciencesisaprivately-heldbiopharmaceuticalcompanybasedinCambridge,Massachusetts,anddevelopsdrugstotreatpain,inflammation,anxietyandotherdiseasesusingitsexpertiseinnovelionchannels.HydraBiosciences’proprietaryplatformsenablethecompanytoidentifyanddevelopdrugcandidatesthataddresssignificantunmetmedicalneeds.
医药网新闻